Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL28164691 | 0.88 | CYP19A1 (0.61) | CYP19A1RAB9AHPGDSMN1; SMN2STS | |
| SCHEMBL9078420 | 0.85 | CYP19A1 (0.69) | CYP19A1RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL28017226 | 0.84 | CYP19A1 (0.68) | CYP19A1HPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9942119 | 0.84 | CYP19A1 (0.61) | CYP19A1RAB9ANPC1HPGDSTS | |
| SCHEMBL1301606 | 0.83 | CYP19A1 (0.71) | CYP19A1RAB9AHPGDSTSALDH1A1 | |
| SCHEMBL27820726 | 0.83 | CYP19A1 (0.71) | CYP19A1RAB9AHPGDSTSALDH1A1 | |
| SCHEMBL7407605 | 0.83 | CYP19A1 (0.63) | CYP19A1RAB9AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL27833119 | 0.82 | CYP19A1 (0.67) | CYP19A1HPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5049441 | 0.81 | CYP19A1 (0.71) | CYP19A1RAB9AHPGDSTSALDH1A1 | |
| SCHEMBL27761137 | 0.81 | STS (0.57) | CYP19A1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-6071538-A | TRANSPORTATION ACROSS CELL MEMBRANE OR LIPID BILAYER | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-06-06 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20050255138-A1 | Active agent transport systems | MHR INSTITUTIONAL PARTNERS IIA LP | 2005-11-17 | — | — | US | disclosed |
| US-6916489-B2 | Active agent transport systems | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1021169-A4 | ACTIVE AGENT TRANSPORT SYSTEMS | EMISPHERE TECH INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030133953-A1 | Active agent transport systems | EMISPHERE TECHNOLOGIES, INC. | 2003-07-17 | — | — | US | disclosed |
| US-6099856-A | INCREASED BIOAVAILABLE | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-1021169-A1 | ACTIVE AGENT TRANSPORT SYSTEMS | Emisphere Technologies, Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6071538-A | TRANSPORTATION ACROSS CELL MEMBRANE OR LIPID BILAYER | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| WO-1999016427-A1 | ACTIVE AGENT TRANSPORT SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998025589-A1 | ACTIVE AGENT TRANSPORT SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5714167-A | REVERSIBLY FORMING SUPRAMOLECULAR COMPLEX OF ACTIVE AGENT WITH PERTURBANT; DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5541155-A | MIXTURES WITH PEPTIDES, MUCOPOLYSACCHARIDES, CARBOHYDRATES, LIPIDS, PESTICIDES, CROMOLYN SODIUM AND DESFERRIOXAMINE | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995028920-A1 | ACIDS AND ACID SALTS AND THEIR USE IN DELIVERY SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050255138-A1 | Active agent transport systems | ABCB11, SLC47A1, ABCB4 | CYP19A1 3639/4885RAB9A 583/4885NPC1 195/4885 |
| US-20030133953-A1 | Active agent transport systems | ABCB11, SLC47A1, ABCB4 | CYP19A1 3639/4885RAB9A 583/4885NPC1 195/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | CYP19A1 3805/4885RAB9A 3841/4885NPC1 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.